Cutaneous Manifestation of Monomorphic Epitheliotropic Intestinal T‐Cell Lymphoma: A Clue to A Gastrointestinal Malignancy

Fan Foon Cheo(Singapore General Hospital), Laura B. Pincus(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Karthik A. Ganapathi(University of California, San Francisco), Aashna Farishta(Rush University Medical Center), Briana M. Garcia(University of California, San Francisco)

Journal of Cutaneous Pathology

April 21, 2026

10.1111/cup.70123

Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

|Journal of Clinical Oncology|2010|487

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

|The Lancet Oncology|2021|428

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247